VistaPharm Recalls Nystatin Oral Suspension Due to Impurity
VistaPharm is recalling Nystatin Oral Suspension because it contains an impurity peak that exceeds approved specifications.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class III recall, which indicates the product is unlikely to cause adverse health consequences. The hazard is a failed impurity specification without reported injuries.
Plain-English summary
VistaPharm, Inc. is recalling Nystatin Oral Suspension, USP, 100,000 units/mL. The product is available in 2 fl.oz. (60mL) bottles and 500,000 units/5mL individual unit dose cups. The recall involves approximately 2,208,500 cups and 18,696 bottles.
The recall was initiated because the product failed impurities and degradation specifications. Specifically, the presence of an impurity peak exceeds the approved specification. The affected lots include 431300, 434000, 432500, 462200, 443800, 445500, 460500, and 461500, with expiration dates ranging from 01/2018 to 09/2017.
The product was distributed nationwide in the US and Puerto Rico. Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on replacement or disposal.
The recalled product
- Product
- Nystatin Oral Suspension, USP, 100,000 units/mL, packaged in a) 2 fl.oz. (60mL) bottles (NDC 66689-008-02), and 500,000 units/5mL individual unit dose cup (NDC 66689-037-01) packaged in b) 50 count unit dose cups/case (NDC 66689-037-50) and c) 100 count unit dose cups/case (NDC…
- Manufacturer
- VistaPharm, Inc.
- Category
- Drug — Antifungal
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- a) Lot #: 431300
- Exp. 01/2018
- b) Lot #: 434000
- 432500
- Exp. 07/2017
- 462200
- Exp. 02/2018 c) Lot #: 443800
- 445500
- Exp. 09/2017
- 460500
- 461500
- Exp. 01/2018.
Distribution
Related recalls
Same manufacturer · VistaPharm, Inc.
See all →- ModeratePrescription pyridostigmine bromide oral solution recalled for out-of-specification preservative
FDA (Drugs) · 2022-11-02
- ModerateClobazam Oral Suspension Recalled for Failed Stability Specifications
FDA (Drugs) · 2022-01-26
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity
FDA (Drugs) · 2020-10-14
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Exceeding Specifications
FDA (Drugs) · 2020-07-15
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Peak
FDA (Drugs) · 2020-07-15
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Failures
FDA (Drugs) · 2018-12-26
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Peak
FDA (Drugs) · 2020-07-15
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity
FDA (Drugs) · 2020-10-14
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Exceeding Specifications
FDA (Drugs) · 2020-07-15
- ModerateVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Test Failures
FDA (Drugs) · 2013-08-28
- SevereVistaPharm Recalls Nystatin Oral Suspension Due to Water Contamination
FDA (Drugs) · 2017-02-08